Abstract
Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
Keywords: Major depression, drug treatment, anti-psychotics, toxicity
Current Drug Safety
Title: Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects
Volume: 5 Issue: 3
Author(s): Charles DeBattista and Kristina DeBattista
Affiliation:
Keywords: Major depression, drug treatment, anti-psychotics, toxicity
Abstract: Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
Export Options
About this article
Cite this article as:
DeBattista Charles and DeBattista Kristina, Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects, Current Drug Safety 2010; 5(3) . https://dx.doi.org/10.2174/157488610791698325
DOI https://dx.doi.org/10.2174/157488610791698325 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory
Endocrine, Metabolic & Immune Disorders - Drug Targets Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism Action Mechanism of Antihistamines and the New Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
Cardiovascular & Hematological Disorders-Drug Targets Multidrug Transporters as Drug Targets
Current Drug Targets The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Biofilm Inhibition of Spoilage Bacteria by Argentinean Fruit Juices with Antihypertensive Activity
Current Pharmaceutical Biotechnology The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Diabetes-Induced Alterations in Renal Medullary Microcirculation and Metabolism
Current Diabetes Reviews Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy